Insulet Corp (PODD)
256.33
-7.02
(-2.67%)
USD |
NASDAQ |
Dec 18, 16:00
257.10
+0.77
(+0.30%)
Pre-Market: 08:44
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 17.98B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 22.28% |
| Valuation | |
| PE Ratio | 43.89 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 9.874 |
| Price to Book Value | 16.08 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.251 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 61.31% |
Profile
| Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide. |
| URL | https://www.insulet.com |
| Investor Relations URL | https://investor.insulet.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 21, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide. |
| URL | https://www.insulet.com |
| Investor Relations URL | https://investor.insulet.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Equity Style | Mid Cap/Growth |
| Next Earnings Release | Feb. 21, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |